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ABSTRACT
This report addresses the concept that permissible HLA mismatching, that is, mismatches that do not generate
an allogeneic response, in hematopoietic stem cell transplantation (HCT) can be determined with structural
similarity of polymorphic regions. We have applied the triplet version of a structural algorithm called
HLAMatchmaker, which considers short sequences involving polymorphic amino acid residues on themolecular
surface as key elements of immunogenic epitopes. The triplet matching effect was analyzed in a National
Marrow Donor Program dataset consisting of 744 unrelated hematopoietic cell transplantation cases with
1 HLA-A, -B, or -C mismatch and 1690 fully HLA-A, -B, -C, -DR, or -DQ allele matched cases. In multivariate
models adjusting for other significant clinical risk factors, the degree of triplet mismatching did not significantly
correlate with patient survival, engraftment, or acute graft-versus-host disease (aGVHD). Other structurally
based strategies should be pursued to identify permissible HLA mismatches in HCT.
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Although the outcome of unrelated donor hemato-
poietic cell transplants (HCT) can be optimized by
matching for HLA-A, -B, -C, and -DRB1 alleles,
many patients have no access to such matched donors.
A recent analysis of the National Marrow Donor
Program (NMDP) experience has shown that about
one-quarter of patients received 1 allele mismatched
HCT primarily involving the HLA-A, -B, and -C
loci [1]. Patients with such transplants have, however,
less successful engraftment, more acute graft-versus-
host disease (aGVHD) and lower survival rates [1-4].
This problem might be overcome with HCT from
donors with ‘‘permissible’’ mismatches that do not in-1064crease patient morbidity and mortality. Permissive
mismatches can be defined as HLA allele differences
between the donor and recipient that do not elicit an
allogeneic GVHD or rejection response.
At least 2 studies have considered structural simi-
larity among HLA allelic products as a means of pre-
dicting improved outcome. In a previous analysis of
NMDP data, HLA mismatching within a serologic
crossreactive group (CREG) at HLA-A or -B was
not associated with a survival benefit in comparison
to mismatches outside a CREG [5]. The findings sug-
gest that serologically defined similarities between
mismatched HLA class I antigens are not indicative
of permissive mismatches. A second approach to define
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that applies the so-called distance index of Risler [6] to
assess functional similarities between amino acid substi-
tutions on disparate HLA molecules [7]. Similarity, as
measured by a low Histocheck score, offered no benefit
to patients with bone marrow transplants from class I
mismatched donors [8]. In addition, a recent report by
Kawase et al. [9] suggested that certain amino acid
positions in HLA class I mismatches contribute to the
severity of GVHD. At present, the criteria for HLA
mismatch permissibility are not readily defined [10].
HLAMatchmaker is a matching algorithm that
considers the structural basis of epitopes on HLA an-
tigens. Each class I HLA antigen is viewed as a string
of short sequences (triplets) involving polymorphic
amino acid residues on the molecular surface. These
residues are hypothesized to comprise key elements
of epitopes that can induce HLA-specific antibodies
[11,12]. Donor-recipient compatibility is assessed by
determining which triplets in corresponding sequence
positions are different. The degree of structural com-
patibility of an HLA mismatch can vary between 0 or
few triplets to .15 triplets. The triplet matching con-
cept has clinical relevance as suggested by an analysis
of 2 large kidney transplant databases showing that
HLA-A, -B mismatched kidneys that are compatible
at the triplet level exhibit almost identical graft survival
rates as the 0 HLA-A, -B antigen mismatches defined
by conventional criteria [13]. Moreover, the degree
of humoral sensitization correlates with the number
of mismatched triplets on immunizing HLA antigens
[14-16]. HLAMatchmaker has also been used in refin-
ing and expanding platelet donor selection for refrac-
tory, thrombocytopenic patients [17,18].
We have addressed the hypothesis that matching at
the structural level using HLAMatchmaker permits
the identification of permissible mismatches for
HCT. This report describes our analysis of the effect
of class I HLA mismatches with minimal mismatched
triplets on HCT outcome.
MATERIALS AND METHODS
NMDP Database and Patient Characteristics
Patients reported to the NMDP who were trans-
planted between 1988 and 2003 and fully HLA-typed
through the NMDP’s ongoing retrospective high
resolution typing project were included in this analysis
(Table 1). Eligible diagnoses included acute lympho-
blastic leukemia (ALL, N5 581), acute myeloid leuke-
mia (AML, N 5 676), chronic myeloid leukemia
(CML, N 5 954), and myelodysplastic syndrome
(MDS, N 5 223). Early-stage disease (N 5 1046)
was defined as AML and ALL in the first complete re-
mission, CML in the first chronic phase, and MDS
subtype refractory anemia. Intermediate-stage disease
(N 5 937) was AML or ALL in the second or subse-quent complete remission or in the first relapse, and
CML in the accelerated phase or second chronic
phase. Advanced phase disease (N 5 448) was AML
in the second or higher relapse or primary induction
failure, CML in the blast phase, MDS subtypes refrac-
tory anemia with excess blasts or in transformation, or
MDS, not otherwise classified. All patients received
standard myeloablative conditioning regimens.
Patients undergoing conditioning regimens of
lower intensity, second or subsequent transplantation,
or surviving patients who did not provide signed, in-
formed consent to allow analysis of their clinical data
or HLA typing of stored NMDP Research Repository
samples were excluded. All surviving recipients in-
cluded in this analysis were retrospectively contacted,
and provided informed consent for participation in
the NMDP research program. Informed consent was
waived by the NMDP institutional review board for
all deceased recipients. To adjust for the potential
bias introduced by exclusion of nonconsenting surviv-
ing patients, a modeling process randomly excluded
the same percentage of deceased patients using a biased
coin randomization with exclusion probabilities based
on characteristics associated with not providing con-
sent for use of the data in survivors [1].
HLA Matching at the Triplet Level
High-resolution typing was performed retrospec-
tively through the NMDP Donor/Recipient Pair
Project for HLA-A, -B, -C, -DRB1, and -DQB1, as
previously described [13]. To evaluate the role of trip-
let mismatching at the HLA class I loci (HLA-A, -B,
and -C) the study population was restricted to cases
either fully matched for HLA-A, -B, -C, -DRB1, and
-DQB1 alleles (10 of 10 matches) or with a single mis-
match at HLA class I (9 of 10 allele/antigen matches).
A total of 2434 donor-recipient pairs were included in
the analysis, 1690 of which were 10 of 10 HLA
matches. There were 744 donor-recipient pairs that
were 9 of 10 HLA matched with 1 class I mismatch:
242 (33%) for HLA-A, 97 (13%) for HLA-B, and
405 (54%) for HLA-C (Table 2).
The triplet version of HLAMatchmaker was used
to assess the degree of structural compatibility be-
tween 1-allele mismatches [11]. Table 2 shows the dis-
tribution of the numbers of mismatched triplets in the
host-versus-graft (HVG) and graft-versus-host (GVH)
direction among the allele mismatches for HLA-A, -B,
and -C. The 0-triplet mismatch group comprised rel-
atively more HLA-B allele mismatches than the other
triplet mismatch groups.
Clinical Endpoints
The primary endpoint of this study was disease-
free patient survival; engraftment and aGVHD were
secondary endpoints. Two parameters were used to
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0 Allele MM 0 Triplet MM 1 Triplet MM 2-3 Triplet MM 4-5 Triplet MM 61 Triplet MM
Number of patients 1690 241 140 143 102 118
Number of centers 105 72 59 54 44 47
Median age (years) (range) 35(\1-65) 32(\1-60) 35(1-58) 30(\1-57} 32(1-59) 28(2-65)
Male gender 960 (57%) 124 (51%) 73 (52%) 80 (56%) 56 (55%) 64 (54%)
$90 Karnofsky score 1225 (75%) 168 (71%) 101(74%) 100 (72%) 79 (81%) 86 (74%)
Disease at transplant
AML 452 (27%) 72 (30%) 41 (29%) 51 (36%) 27 (27%) 33 (28%)
ALL 382 (23%) 64 (26%) 30 (22%) 40 (28%) 33 (32%) 32 (27%)
CML 695 (41%) 89 (37%) 62 (44%) 38 (26%) 32 (31%) 38 (32%)
MDS 161 ( 9%) 16 ( 7%) 7 ( 5%) 14 (10%) 10 (10%) 15 (13%)
Disease status
Early 761 (45%) 96 (40%) 64 (46%) 41 (29%) 36 (35%) 48 (41%)
Intermediate 631 (37%) 104 (43%) 54 (38%) 72 (50%) 34 (33%) 42 (36%)
Advanced 296 (18%) 41 (17%) 22 (16%) 30 (21%) 32 (32%) 27 (23%)
Graft type
Marrow 1561 (92) 223 (93) 126 (90) 128 (90) 97 (95) 109 (92)
Peripheral blood 129 (8) 18 (7) 14 (10) 15 (10) 5 (5) 9 (8)
Donor/recipient CMV match
Negative/negative 619 (37) 73 (30) 51 (37) 53 (37) 31 (30) 44 (37)
Negative/positive 463 (27) 71 (30) 39 (28) 36 (25) 29 (28) 32 (27)
Positive/negative 277 (16) 44 (18) 24 (17) 25 (17) 17 (17) 15 (13)
Positive/positive 280 (17) 49 (20) 24 (17) 28 (20) 22 (22) 23 (20)
Unknown 51 (3) 4 (2) 2 (1) 1 (1) 3 (3) 4 (3)
Donor/recipient sex match
Male/Mmle 665 (39) 82 (34) 44 (31) 46 (32) 30 (29) 44 (37)
Male/female 407 (24) 61 (25) 35 (25) 29 (20) 29 (28) 33 (28)
Female/male 295 (18) 42 (18) 29 (21) 34 (24) 26 (26) 20 (17)
Female/female 323 (19) 56 (23) 32 (23) 34 (24) 17 (17) 21 (18)
GVHD prophylaxis
FK506 ± other 339 (20) 58 (24) 33 (23) 29 (20) 19 (19) 17 (14)
CSA 1 MTX ± other 984 (58) 133 (55) 77 (55) 64 (45) 55 (54) 66 (56)
CSA± other (no MTX) 63 (4) 4 (2) 4 (3) 4 (3) 1 (1) 4 (3)
T cell depletion 285 (17) 44 (18) 26 (19) 43 (30) 27 (26) 30 (26)
Other 19 (1) 2 (1) 0 3 (2) 0 1 (1)
MM indicates mismatches; CSA, cyclosporine; MTX, methotrexate.assess successful engraftment: blood neutrophil counts
of$500/mm3 for 3 consecutive days and blood platelet
counts reaching $20,000  109/L. The incidence of
grades II-IV and III-IV aGVHD disease was deter-
mined during the first 100 days posttransplant. Events
were summarized by the cumulative incidence esti-
mate with death as a competing risk.
Statistical Methods
The statistical analyses of transplant outcome pa-
rameters comparing matching in HVG and GVH
directions were similar to those in a previous report
on CREG matching [5]. To compare pretransplant
characteristics for discrete factors, the number of cases
and their respective percentages were calculated and
chi-square testing was done to compare the HLA
matched, triplet matched, and triplet mismatched
groups. For continuous factors, the median and ranges
were calculated and the Kruskal-Wallis test was used
to analyze differences between HLA matched, triplet
matched, and triplet mismatched groups. Probabilities
of disease-free survival (DFS) were calculated using
the Kaplan-Meier estimator with variance estimatedby Greenwood’s formula. Comparisons of survival
curves were done with the log-rank test.
Multivariate analyses were performed using the
proportional hazards model to compare the HLA
matched, triplet matched, and triplet mismatched
groups. Models were fit to determine which risk factors
may be related to a given outcome. All variables were
tested for the affirmation of the proportional hazards
assumption. Factors violating the proportional hazards
assumption were adjusted using time-dependent vari-
ables or stratification before the stepwise model build-
ing approach was used in developing models for the
primary and secondary outcomes. Five patients were
excluded from the multivariate models because of
missing clinical and/or outcome data.
RESULTS
Engraftment
Figure 1a and b shows the unadjusted cumulative
percentages of patients with successful neutrophil en-
graftment for the 10 of 10 matched and HVG direction
triplet mismatched groups. There was no significant
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between the 10 of 10 and 9 of 10 allele matched groups
(P5 .33). On day 60 posttransplant, the cumulative in-
cidence of neutrophil engraftment was 94% for the 10
of 10 group, 93% for the 0-triplet mismatches, 93%
for the 1-triplet mismatches, 90% for the 2-3 triplet
mismatches, 95% for the 4-5 triplet mismatches, and
88% for the $6 triplet mismatches. The differences
between the groups were not statistically significant.
Figure 2a and b shows the unadjusted cumulative
percentages of patients with blood platelet counts
reaching $20,000/mm3 for the 10 of 10 matched and
HVG direction triplet mismatched groups. The 9 of
10 matches had significantly lower success rates than
the 10 of 10 matches (after 100 days: 65% versus
72%, P 5 .001). At 100 days, the engraftment rates
were 67% for the 0-triplet mismatches, 63% for the
1-triplet mismatches, 68% for the 2-3 triplet mis-
matches, 61% for the 4-5 triplet mismatches, and
61% for the $6 triplet mismatches. The platelet en-
graftment differences observed between the triplet
mismatched groups were not statistically significant.
Acute GVHD
The cumulative incidence of grade II-IV aGVHD
was higher for the 9 of 10 matches than the 10 of 10
matches, 52% versus 49% after 100 days, but this dif-
ference was not statistically significant (P 5 .15)
(Figure 3a). However, in a multivariate analysis adjust-
ing for other risk factors, the 9 of 10 matches had
a significantly higher risk for grade II-IV (P 5 .008)
and grade III-IV (P \ .001) GVHD than the 10 of
10 matches (Table 3). Among the 9 of 10 matches,
the 0-triplet mismatches in the GVH direction had
a similar incidence of grade II-IV aGVHD as the 10
of 10 matches: 47% versus 49% after 100 days
(Figure 3b). The other triplet mismatches had a higher
incidence of aGVHD disease, namely 1 triplet (54%),










242 (33%) 97 (13%) 405 (54%) 744
HVG direction
0 Triplets 67 (29%) 76 (33%) 86 (38%) 229
1 Triplet 45 (32%) 9 (6%) 89 (62%) 143
2-3 Triplets 32 (22%) 5 (3%) 108 (75%) 145
4-5 Triplets 37 (32%) 4 (4%) 73 (64%) 114
61 Triplets 61 (54%) 3 (3%) 49 (43%) 113
GVH direction
0 Triplets 73 (30%) 73 (30%) 95 (40%) 241
1 Triplet 44 (31%) 14 (10%) 82 (59%) 140
2-3 Triplets 37 (26%) 6 (4%) 100 (70%) 143
4-5 Triplets 36 (35%) 1 (1%) 65 (64%) 102
61 Triplets 52 (44%) 3 (3%) 63 (53%) 118
GVH indicates graft-versus-host; HVG, host-versus-graft.2-3 triplets (58%), 4-5 triplets (53%), and $6 triplets
(53%), but were not statistically different.
A multivariate analysis showed that the risk of
grade II-IV GVH disease for the 0, 1, 4-5, and$6 trip-
let mismatches and the risk of grade III-IV GVH
disease for the 0 and $6 triplet mismatches was not
statistically different when compared to the 10 of 10
matched cohort (Table 3). However, when the individ-
ual triplet mismatch groups were compared, none of
the groups were significantly different from each other
(P 5 .16 and P 5 .13 for grades II-IV and III-IV, re-
spectively). Altogether, this multivariate analysis sug-
gests that the degree of triplet mismatching among
the 9 of 10 matches does not correlate with the risk
for aGVHD.
DFS
DFS was significantly lower for the 9 of 10 matches
than the 10 of 10 matches (Figure 4a). Two-year DFS
was 32% and 40% for 9 of 10 and 10 of 10 groups,
respectively (P \ .001). Triplet matching in the
GVH direction within the 9 of 10 matches did not im-
prove DFS (Figure 4b). The 2-year unadjusted DFS
rates were 31% for the 0-triplet mismatches, 36%
for the 1-triplet mismatches, 34% for the 2-3 triplet
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Figure 1. Matching effect on neutrophil engraftment. (A) The 9 of
10 matches have slightly lower rates than 10 of 10 matches (at 28
days P5 .33, NS). (B) Effect of triplet mismatching in the HVG di-
rection. Although the 61 triplet mismatch group had the lowest neu-
trophil engraftment rate, the differences between the different match
groups were not statistically significant.
1068 R. Duquesnoy et al.29% for the $6 triplet mismatches. A similar analysis
showed that triplet mismatching in the HVG direction
did not benefit DFS (data not shown).
Multivariate analysis showed that the overall risk of
treatment failure (relapse or death, the inverse of DFS)
(P 5 .008) was significantly higher after 9 of 10 than
after10 of 10 matched transplants (Table 4). The eval-
uation of individual triplet groups revealed that the
difference in DFS between some triplet mismatch
groups and the 10 of 10 matched group did not reach
statistical significance (P . .01), that is, 1, 2-3, and
$6 triplet mismatches. However, when the individual
triplet mismatch groups were compared, none were
significantly different from each other (P5 .62). Alto-
gether, this multivariate analysis suggests that the
degree of triplet mismatching among the 9 of 10
matches does not influence the likelihood of DFS.
DISCUSSION
This study confirms previous reports that a single
class I HLA mismatch has an adverse effect on HCT
outcome as manifested by less engraftment, more
aGVHD and lower patient survival [1,3,4]. The goal
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Figure 2. Matching effect on platelet engraftment. (A) The 9 of 10
match group had a significantly lower engraftment rate than the 10
of 10 matches (P 5 .001 after 100 days). (B) Effect of triplet match-
ing; the 4-5 and 6 triplet mismatch groups had the lowest platelet en-
graftment rates but the differences between the triplet groups were
not statistically significant.missive class I mismatches that result in the same out-
come as the fully matched transplants or, at least, with
better outcomes than class I mismatches with higher
structural dissimilarity. However, the results of this
analysis suggest that matching for HLAMatchmaker
assigned triplets does not benefit HCT outcome.
HLA Matchmaker considers compatibility at the
humoral immune level, that is, a structural identification
of antibody accessible epitopes exposed on the HLA
molecular surface. The original version uses triplets,
that is, linear sequences of 3 amino acids, at least 1 of
which is an antibody-accessible polymorphic residue
[11]. The triplet version does not address compatibility
at the cellular immune level involving T cell activation
influenced by structural polymorphisms in the pep-
tide-binding groove and on the HLA molecular surface.
Alloreactive T cells play a dominant role in GVHD and
their T cell receptors recognize peptides presented by
HLA molecules. One might expect that 0-triplet mis-
matches would be structurally more similar to the corre-
sponding self-alleles of the patient and may therefore
bind the same peptide repertoire unless the peptide-
binding groove has significant amino acid differences.
The literature has many reports describing alloreac-
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Days after transplant
Figure 3. HLA matching effect on acute grade II-IV GVHD. (A)
The 9 of 10 match group had a statistically insignificant higher inci-
dence than the 10 of 10 matches; 52% versus 49% after 100 days, P5
.15. (B) Effect of triplet mismatching in the GVH direction. There
was no statistically significant correlation between the number of
mismatched triplets and the incidence of aGVHD.
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alloreactive T cell clones have been described that are
specific for HLA-A2, -B7, or -Bw4 [19-23]; these anti-
gens carry unique triplets: 66RKV, 177DK, and
82ALR, respectively (the numbers indicate the HLA
protein sequence position and amino acids are shown
with the standard 1-letter code). Although triplet
matching improves outcome in renal and corneal trans-
plantation [13,24] and reduces humoral sensitization
[14-16], we must conclude that triplet matching is not
useful in the selection of mismatched donors for HCT.
It should be pointed out that HLAMatchmaker
considers a considerable proportion of polymorphic
residues involved with peptide binding. The peptide-
binding sites of class I HLA molecules comprise
32-36 amino acid residues [25-28], 25 of them are
polymorphic. HLAMatchmaker includes 18 of these
polymorphic residues to define triplets accessible to
antibodies; polymorphisms in nonexposed sequence
positions 24, 73, 95, 97, 99, 113, and 114 are not con-
sidered. Certain positions in the peptide-binding
groove have been reported to be relevant for HCT.
For instance, amino acid differences in sequence posi-
tions 116 and 156 have been shown to increase the risk
of GVHD and patient mortality after HCT [29-31].
This structural matching algorithm includes triplets
in positions 116 and 156.
At this time, the application of a structurally based
HLA mismatch permissibility algorithm for HCT re-
Table 3.Multivariate Analysis Comparing aGVHD for 10 of 10Matches




(95% confidence interval) P-value
Grade II-IV GVHD
10 of 10 matches 168 1.00
0 Triplet mismatches 241 1.04 (0.85-1.26) .72
1 Triplet mismatches 140 1.16 (0.92-1.46) .22
2-3 Triplet mismatches 142 1.46 (1.16-1.84) .001
4-5 Triplet mismatches 102 1.36 (1.03-1.79) .031
$6 Triplet mismatches 117 1.17 (0.91-1.50) .23
Grade III-IV GVHD
10 of 10 matches 168 1.00
0 Triplet mismatches 241 1.23 (0.97-1.57) .10
1 Triplet mismatches 140 1.46 (1.09-1.95) .01
2-3 Triplet mismatches 142 1.93 (1.47-2.54) .0001
4-5 Triplet mismatches 102 1.60 (1.14-2.250 .007
$ 6 Triplet mismatches 117 1.39 (1.00-1.92) .048
Adjusted factors: disease, GVHD prophylaxis, graft type, Karnofsky
score, year of transplant, recipient gender. The overall compari-
son of 10 of 10 matches versus all triplet groups was significantly
different (chi-square test,P5 .008 and P\ .0001 for grades II-IV
and III-IV, respectively). The overall comparison of individual
triplet mismatch groups found that none were significantly
different from each other (chi-square test, P 5 .16 and P 5 .13
for grades II-IV and III-IV, respectively).
aGVHDindicates acute graft-versus-host disease; GVH, graft-
versus-host.mains elusive. Because HCT outcome is primarily
affected by cellular immune mechanisms mediated by
various types of T-lymphocytes and natural killer
(NK) cells, the algorithm must take in account all
amino acid polymorphisms of HLA. This includes
the residues in the peptide-binding groove that are im-
portant in determining the repertoire of HLA bound
peptides [28,32,33], the amino acids on the a1 and
a2 helices that contact the TCR of alloreactive lym-
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Figure 4. HLA matching effect on patient DFS. (A) The 9 of 10
matches had significantly lower survival rates than the 10 of 10
matches (P 5 .001). (B) Triplet matching did not increase patient
survival rates.
Table 4.Multivariate Analysis Comparing DFS for 10 of 10 and 9 of 10
Matches with Triplet Mismatches in the GVH Direction
Match group N
Relative risk
(95% confidence interval) P-value
10 of 10 matches 1687 1.00
0 Triplet mismatches 241 1.26 (1.07-1.48) .005
1 Triplet mismatches 140 1.13 (0.91-1.39) .263
2-3 Triplet mismatches 142 1.17 (0.95-1.43) .147
4-5 Triplet mismatches 102 1.39 (1.10-1.75) .005
$6 Triplet mismatches 117 1.14 (0.91-1.42) .264
Adjusted factors: disease, disease stage, recipient age, GVHD pro-
phylaxis, Karnofsky score, recipient gender. The overall compar-
ison of 10 of 10 matches versus all triplet groups was significantly
different (chi-square test, P 5 .008). The overall comparison of
individual triplet mismatch groups found that none were signif-
icantly different from each other (chi-square test, P 5 .62).
GVH indicates graft-versus-host; DFS, disease-free survival.
1070 R. Duquesnoy et al.affect NK function [38-41]. With this complexity, the
development of a permissible mismatch strategy repre-
sents a considerable challenge.
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